{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:22:43Z","timestamp":1747149763307,"version":"3.40.5"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health, Czech Republic","award":["00098892"],"award-info":[{"award-number":["00098892"]}]},{"name":"Charles University PROGRES","award":["Q40\/08"],"award-info":[{"award-number":["Q40\/08"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Twenty percent of patients with high\u2010tumor\u2010burden (HTB) follicular lymphoma (FL) develop progression\/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years since POD event. Rituximab maintenance was proven to reduce relapse rate in responding FL, but its role on preventing POD was not defined. We analyzed 1360 HTB\u2010FL patients from the Czech Lymphoma Study Group registry treated with frontline rituximab\u2010containing regimen. Of those, 950 cases received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R\u2010CHOP) and achieved complete or partial remission: 712 patients received rituximab maintenance (MAINT) and 238 were a historical observational cohort (OBS). We have proposed a modified POD24 (mPOD24) endpoint for the chemosensitive patients calculated from the end\u2010of\u2010induction (EOI). Survival rates since EOI were as follows: 5\u2010year overall survival (OS) 86.2%\u00a0versus 94.5% in the OBS and MAINT groups, respectively (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001) and 5\u2010year progression\u2010free survival 58.5% (OBS) and 75.4% (MAINT) (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001). The Cox proportional hazards model showed a decrease in mPOD24 incidence in the MAINT group with the overall hazard rate reduced by 56% (hazard ratio = 0.44; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001). The cumulative incidence of mPOD24 was reduced from 24.1% in OBS to 10.1% in MAINT (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001). Comparison of non\u2010mPOD24 cases showed OS similar to that in the general population. Rituximab maintenance given after R\u2010CHOP resulted in a 2.4\u2010fold reduction in mPOD24 incidence. Once the non\u2010POD24 status is achieved, FL does not shorten the patients\u2019 life expectancy.<\/jats:p>","DOI":"10.1002\/jha2.60","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T17:58:07Z","timestamp":1596218287000},"page":"170-180","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R\u2010CHOP"],"prefix":"10.1002","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9861-3117","authenticated-orcid":false,"given":"V\u00edt","family":"Proch\u00e1zka","sequence":"first","affiliation":[{"name":"Department of Hemato\u2010Oncology, Faculty of Medicine and Dentistry University Hospital in Olomouc  Olomouc Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-6188","authenticated-orcid":false,"given":"David","family":"Belada","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine \u2013 Hematology University Hospital  Hradec Kr\u00e1lov\u00e9 Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-7769","authenticated-orcid":false,"given":"Andrea","family":"Jan\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Masaryk University Hospital Brno  Brno Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3526-2257","authenticated-orcid":false,"given":"Kate\u0159ina","family":"Bene\u0161ov\u00e1","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine \u2013 Hematology First Faculty of Medicine and General Teaching Hospital  Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2034-0769","authenticated-orcid":false,"given":"Heidi","family":"Mocikov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine Charles University  Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juraj","family":"\u010eura\u0161","sequence":"additional","affiliation":[{"name":"Department of Hemato\u2010Oncology University Hospital Ostrava  Ostrava Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Pirnos","sequence":"additional","affiliation":[{"name":"Department of Oncology Hospital \u010cesk\u00e9 Bud\u011bjovice  \u010cesk\u00e9 Bud\u011bjovice Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate\u0159ina","family":"Kope\u010dkov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology University Hospital Motol  Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edt","family":"Campr","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine University Hospital in Motol  Prague Czech Republic"},{"name":"Second Faculty of Medicine Charles University  Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-4183","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"F\u00fcrst","sequence":"additional","affiliation":[{"name":"Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science Palack\u00fd University  Olomouc Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0517-2691","authenticated-orcid":false,"given":"Robert","family":"Pytl\u00edk","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine \u2013 Hematology First Faculty of Medicine and General Teaching Hospital  Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-6250","authenticated-orcid":false,"given":"Alice","family":"S\u00fdkorov\u00e1","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine \u2013 Hematology University Hospital  Hradec Kr\u00e1lov\u00e9 Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5959-2539","authenticated-orcid":false,"given":"Jozef","family":"Michalka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Masaryk University Hospital Brno  Brno Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Dlouh\u00e1","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine \u2013 Hematology First Faculty of Medicine and General Teaching Hospital  Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5779-1139","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Papaj\u00edk","sequence":"additional","affiliation":[{"name":"Department of Hemato\u2010Oncology, Faculty of Medicine and Dentistry University Hospital in Olomouc  Olomouc Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-6073","authenticated-orcid":false,"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine \u2013 Hematology First Faculty of Medicine and General Teaching Hospital  Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_9_2_1","DOI":"10.1182\/blood-2016-01-643569"},{"doi-asserted-by":"publisher","key":"e_1_2_9_3_1","DOI":"10.1007\/s00277-017-3218-0"},{"doi-asserted-by":"publisher","key":"e_1_2_9_4_1","DOI":"10.1002\/ajh.24937"},{"issue":"5","key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow\u2010up","volume":"27","author":"Dreyling M","year":"2016","journal-title":"Ann Oncol"},{"doi-asserted-by":"publisher","key":"e_1_2_9_6_1","DOI":"10.6004\/jnccn.2019.0029"},{"doi-asserted-by":"publisher","key":"e_1_2_9_7_1","DOI":"10.1200\/JCO.2012.45.0866"},{"doi-asserted-by":"publisher","key":"e_1_2_9_8_1","DOI":"10.1016\/S0140-6736(12)61763-2"},{"doi-asserted-by":"publisher","key":"e_1_2_9_9_1","DOI":"10.1016\/S0140-6736(10)62175-7"},{"doi-asserted-by":"publisher","key":"e_1_2_9_10_1","DOI":"10.1200\/JCO.2017.74.1652"},{"doi-asserted-by":"publisher","key":"e_1_2_9_11_1","DOI":"10.1007\/s00277-020-04025-2"},{"issue":"1","key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2018-99-113675","article-title":"Frontline therapy with bendamustine and rituximab (BR) in follicular lymphoma: prognosis among patients with progression of disease by 24 months (POD24) is poor with majority having transformed lymphoma","volume":"132","author":"Freeman CL","year":"2018","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_9_13_1","DOI":"10.1200\/JCO.2014.59.7534"},{"issue":"23","key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V126.23.333.333","article-title":"A clinicogenetic risk model (m7\u2010FLIPI) prospectively identifies one\u2010half of patients with early disease progression of follicular lymphoma after first\u2010line immunochemotherapy","volume":"126","author":"Vindi J","year":"2015","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_9_15_1","DOI":"10.1002\/hon.2438_89"},{"doi-asserted-by":"publisher","key":"e_1_2_9_16_1","DOI":"10.1182\/blood-2018-08-822148"},{"doi-asserted-by":"publisher","key":"e_1_2_9_17_1","DOI":"10.1200\/JCO.18.02365"},{"issue":"3","key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/10428194.2016.1213834","article-title":"Frontline intensive chemotherapy improves outcome in young, high\u2010risk patients with follicular lymphoma: pair\u2010matched analysis from the Czech Lymphoma Study Group Database","volume":"58","author":"Proch\u00e1zka V","year":"2016","journal-title":"Leukemia Lymphoma"},{"issue":"3","key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1080\/10428194.2018.1508672","article-title":"Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry \u2020","volume":"60","author":"Obr A","year":"2018","journal-title":"Leukemia Lymphoma"},{"issue":"21","key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood.V122.21.4387.4387","article-title":"Impact of rituximab maintenance schedule on prognosis in first line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Group (CLG) Database","volume":"122","author":"Janikova A","year":"2013","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_9_21_1","DOI":"10.1016\/j.leukres.2018.08.019"},{"doi-asserted-by":"publisher","key":"e_1_2_9_22_1","DOI":"10.1200\/JCO.1999.17.4.1244"},{"doi-asserted-by":"publisher","key":"e_1_2_9_23_1","DOI":"10.1016\/0140-6736(93)93073-A"},{"issue":"3","key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-020-0299-0","article-title":"Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single\u2010center experience","volume":"10","author":"Mozas P","year":"2020","journal-title":"Blood Cancer J"},{"issue":"27","key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2012.44.8290","article-title":"Rituximab maintenance compared with observation after brief first\u2010line R\u2010FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi","volume":"31","author":"Vitolo U","year":"2013","journal-title":"J Clin Oncol Official J Am Soc Clin Oncol"},{"doi-asserted-by":"publisher","key":"e_1_2_9_26_1","DOI":"10.1200\/JCO.19.01073"},{"issue":"5","key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3324\/haematol.2020.246991","article-title":"Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression","volume":"105","author":"Seymour JF","year":"2020","journal-title":"Haematologica"},{"doi-asserted-by":"publisher","key":"e_1_2_9_28_1","DOI":"10.1111\/bcp.13920"},{"doi-asserted-by":"publisher","key":"e_1_2_9_29_1","DOI":"10.2217\/imt-2017-0147"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1200\/EDBK_239065","article-title":"One size does not fit all: who benefits from maintenance after frontline therapy for follicular lymphoma?","volume":"39","author":"Roschewski M","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"doi-asserted-by":"publisher","key":"e_1_2_9_31_1","DOI":"10.1016\/j.ejca.2017.01.021"},{"issue":"22","key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V128.22.1781.1781","article-title":"Rituximab maintenance after first line immunochemotherapy improves overall survival in patients with follicular lymphoma","volume":"128","author":"Vilmar A","year":"2016","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_9_33_1","DOI":"10.1182\/blood-2017-11-816405"},{"doi-asserted-by":"publisher","key":"e_1_2_9_34_1","DOI":"10.1016\/j.ejca.2019.12.006"},{"issue":"9","key":"e_1_2_9_35_1","first-page":"1199","article-title":"New developments in the treatment of follicular lymphoma","volume":"60","author":"Leonard JP.","year":"2019","journal-title":"Rinsho Ketsueki Jpn J Clin Hematology"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjha2.60","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.60","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.60","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.60","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:16:52Z","timestamp":1693891012000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.60"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1002\/jha2.60"],"URL":"https:\/\/doi.org\/10.1002\/jha2.60","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"type":"print","value":"2688-6146"},{"type":"electronic","value":"2688-6146"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"2020-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}